Synaptic Vesicle Cycling Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic vesicle (SV) cycling is the fundamental process by which neurotransmitters are released at synapses. This highly orchestrated cycle involves vesicle docking, priming, fusion, release, and recycling. Dysfunction in any step of this process contributes to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of synaptic vesicle cycling and its impairment in neurodegeneration.
The synaptic vesicle cycle consists of several critical steps:
The SNARE (Soluble NSF Attachment Protein Receptor) complex mediates vesicle fusion:
| Component | Synaptic Vesicle | Presynaptic Membrane | Function |
|---|---|---|---|
| Synaptobrevin/VAMP | VAMP1, VAMP2 | Vesicle membrane | v-SNARE |
| SNAP-25 | - | Presynaptic membrane | t-SNARE (2 domains) |
| Syntaxin | STX1A, STX1B | Presynaptic membrane | t-SNARE |
| Protein | Gene | Function |
|---|---|---|
| Synaptotagmin-1 | SYT1 | Fast Ca²⁺ sensor (15 µM) |
| Synaptotagmin-2 | SYT2 | Motor nerve terminal sensor |
| Synaptotagmin-7 | SYT7 | Asynchronous release, high affinity |
| Synaptotagmin-9 | SYT9 | Intermediate affinity |
| Protein | Function |
|---|---|
| RIM | Recruiting vesicles, activating Munc13 |
| Munc13 | Priming factor, vesicle maturation |
| Munc18 | Syntaxin chaperone, SM protein |
| ELKS/CAST | Scaffolding, active zone structure |
| Piccolo | Active zone cytoskeleton |
| Bassoon | Active zone organization |
| Protein | Function |
|---|---|
| Clathrin | Coat formation |
| Dynamin | Vesicle scission |
| Amphiphysin | Clathrin adaptor |
| Endophilins | Membrane curvature |
| Synaptojanin | Dephosphorylation, uncoating |
| Auxilin | Hsc70 cofactor for uncoating |
Synaptic vesicles exist in distinct pools:
| Target | Approach | Status |
|---|---|---|
| Synaptotagmin | Ca²⁺-binding domain modulators | Preclinical |
| SNARE complex | Stabilizing compounds | Preclinical |
| Vesicle priming | Munc13 activators | Research |
| Endocytosis | Clathrin inhibitors | Not pursued |
| α-Synuclein | Oligomerization blockers | Clinical trials |
| Component | Gene | Function | Disease Relevance |
|---|---|---|---|
| Synaptobrevin-2 | VAMP2 | v-SNARE | Aβ sensitivity |
| SNAP-25 | SNAP25 | t-SNARE | Botulinum target |
| Syntaxin-1A | STX1A | t-SNARE | Regulated exocytosis |
| Synaptotagmin-1 | SYT1 | Ca²⁺ sensor | AD impaired |
| Synaptotagmin-7 | SYT7 | Modulator | ALS dysregulation |
| Munc13-1 | UNC13A | Priming | Risk gene for ALS |
| Munc18-1 | STXBP1 | SM protein | Essential for release |
| RIM1 | RIMS1 | Active zone | Synaptic plasticity |
| Synapsin | SYN1 | Vesicle tethering | Phosphorylation |
| Dynamin-1 | DNM1 | Scission | Endocytosis |
| Clathrin | CLTC | Coat | SV reformation |
| Synaptojanin | SJIA1 | Uncoating | PD risk gene |
The study of Synaptic Vesicle Cycling Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Südhof TC. The synaptic vesicle cycle. Annu Rev Neurosci. 2004;27:509-547. PMID:15217342
Bellen HJ, Tong C, Tsuda H. 100 years of Drosophila research and its impact on vertebrate neuroscience: a history lesson for the future. Nat Rev Neurosci. 2010;11(7):514-522. PMID:20379211
Chapman ER. How does synaptotagmin trigger neurotransmitter release? Annu Rev Biochem. 2008;77:615-641. PMID:18275379
Bellen HJ, Lu Y, Godena Z, et al. Genetic inhibition of Ca²⁺-triggered neurotransmitter release and synaptic vesicle endocytosis. Nat Neurosci. 2010;13(7):779-786. PMID:20537543
Burre J, Volpicelli-Daley LA. Mechanisms of alpha-synuclein toxicity to synaptic vesicles. J Neurosci. 2018;38(12):2911-2913. PMID:29581380
Sheng J, Ruan Y, Wang J. Dysfunction of synaptic vesicle cycling in Alzheimer's disease. Brain Res Bull. 2020;155:120-129. PMID:31887401
Yang L, Wang ZH, Liu Y, et al. The role of synaptotagmin in Alzheimer's disease. Neurochem Res. 2021;46(12):3193-3204. PMID:34581928
Mousavi M, Barat G, Rüegg MA. The role of α-synuclein in synaptic function. Neurobiol Dis. 2022;170:105753. PMID:35772531
Jackson WS. Selective vulnerability to neurodegenerative disease: the role of protein homeostasis. J Mol Neurosci. 2017;63(3-4):267-280. PMID:29027520
Rothman JS, Kandel ER. Synaptic plasticity and the mechanism of memory. Annu Rev Neurosci. 2020;43:219-237. PMID:32271347
Virmani T, Spiro M, Girguis C, et al. Synaptic vesicle recycling in Parkinson's disease. Mov Disord. 2020;35(7):1113-1124. PMID:32462769
Tokhtaeva E, Capri J, Marcus EA, et al. Syntaxin-1A stability and synaptic vesicle cycling. J Neurosci. 2015;35(46):15492-15504. PMID:26586843
Gundersen V. Protein organization in the synaptic vesicle. Neurochem Res. 2010;35(11):1778-1790. PMID:20927673
Jorfi M, D'errico P, Amin L. Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol. 2019;1118:73-91. PMID:30627928
Schellekens H, Meraviglia V, Cagnotto A. The presynaptic active zone in neurodegeneration. Prog Neurobiol. 2022;208:101862. PMID:35151384
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%